Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 4 PK/PD and efficacy study of Cufence (trientine dihydrochloride) in Wilson's disease
2020-004604-33Phase 4Active
- Sponsor
- Univar Solutions
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trientine in Wilson disease (WD), sponsored by Univar Solutions. Primary endpoint: Plasma trientine concentration. Started Dec 2020; status: active.
02
Drugs
trientine
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2020-004604-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004604-33.